ReviewClinical and molecular hepatology2023
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Review in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Trial
- Diagnostic performance of FIB-6 for identifying FibroScan-defined advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a cross-sectional diagnostic accuracy study.BMC gastroenterology · 2026Article
- Article
- Gut microbiota-derived indole-3-propionic acid alleviates endoplasmic reticulum stress by regulating FMO2 in MASLD.Hepatology communications · 2026Article
- Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- New Treatment Options for MASLD Patients with Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
- Evolution of Multivalent Aptamer Corona for High-Throughput Multiplexed Detection of Multiple Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- I-FABP, citrulline and non-invasive liver dysfunction indices in patients with depression - cross-sectional study results.BMC gastroenterology · 2026Article
- Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastro hep advances · 2026Article
- Effects of red palm oil intervention on serum lipids, hepatic antioxidant capacity and gut microbiota in high-fat diet-fed mice.Open life sciences · 2026Article
- From fatty liver indices to the Zhejiang University index: Re-shaping risk stratification of metabolic liver disease in diabetes.World journal of diabetes · 2025Article
- Diabetes and NAFLD: A Synergistic Threat to Metabolic Health.Advanced pharmaceutical bulletin · 2025Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances.Endocrinology, diabetes & metabolism · 2025Review
- Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis.European journal of medical research · 2025Article
- Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis.Scientific reports · 2025Article
- Metabolic and hepatic biomarkers associated with MASLD in the Chinese population.Scientific reports · 2025Article
- MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality.Scientific reports · 2025Article
- L-Phenylalanine promotes liver steatosis by inhibiting BNIP3-mediated mitophagy.Molecular medicine (Cambridge, Mass.) · 2025Article
- Associations Between Shift Work, Sociodemographic and Lifestyle Characteristics, Body Measurements, and MASLD.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.